# Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients

> **NCT01076803** · PHASE2 · COMPLETED · sponsor: **University Hospital, Ghent** · enrollment: 40 (actual)

## Conditions studied

- Malignant Intestinal Obstruction

## Interventions

- **DRUG:** Lanreotide (acetate)

## Key facts

- **NCT ID:** NCT01076803
- **Lead sponsor:** University Hospital, Ghent
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-10
- **Primary completion:** 2013-07
- **Final completion:** 2013-07
- **Target enrollment:** 40 (ACTUAL)
- **Last updated:** 2014-12-05


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01076803

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01076803, "Efficacy and Safety of Lanreotide 120 Milligram (mg) as a Palliative Treatment of Clinical Symptoms Associated With Malignant Intestinal Obstruction in Inoperable Patients". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT01076803. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*